A 57.1% complete response rate in stage III unresectable NSCLC — a disease where the current standard of care produces complete responses in fewer than 5% of patients — is not a marginal improvement. It is a signal that demands scrutiny, and the CONVERGE Part 1 data presented at ESTRO 2026 deliver exactly that kind of jolt. Only seven patients completed the full treatment regimen of concurrent chemoradiotherapy plus intratumoral JNJ-1900 (NBTXR3) and consolidation durvalumab, so the denominator is brutally small. But 6 of those 7 responded, 4 achieved complete response, and all 7 had controlled disease — numbers that, even at this sample size, sit in a different statistical universe from the PACIFIC-era benchmark.
The mechanistic logic here is worth understanding on its own terms. NBTXR3 consists of hafnium oxide nanoparticles injected once directly into the tumor, then activated by radiotherapy. The hafnium deposits amplify local energy absorption, driving tumor cell death well beyond what radiation alone achieves. That physical destruction then feeds antigen release into a system already primed by durvalumab’s PD-L1 blockade — a sequencing designed to convert an immunologically cold tumor microenvironment into something the adaptive immune system can finish. Stage III NSCLC’s poor complete response history is partly explained by insufficient depth of locoregional kill; this approach attacks that problem at the physics level before immunotherapy ever enters the equation.
The design of CONVERGE itself matters as much as these early numbers. This is a randomized Phase 2, J&J-sponsored, with intratumoral and intranodal injection confirmed as feasible across three academic centers — Penn, NYU Langone, and FirstHealth of the Carolinas. Feasibility in this setting is not trivial; getting nanoparticles into mediastinal nodes under bronchoscopic guidance requires interventional pulmonology infrastructure that not every site carries. The randomized architecture means Part 2 will produce a controlled comparison rather than a single-arm signal, giving regulators something structurally cleaner to evaluate.
The number to track as Part 2 data mature is progression-free survival at 24 months. The PACIFIC trial established durvalumab consolidation’s PFS2 benchmark at roughly 16.9 months. If CONVERGE’s complete responders hold their responses — and absence of progressive disease in the current cohort suggests they might — that figure is the line NBTXR3 must cross to force a label conversation in this indication.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
